The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

INTRODUCTION: As a result of the new treatment paradigm that the haemophilia community will face with the availability of novel (non‐factor) therapies, an updated consensus on ITI recommendations and inhibitor management strategies is needed. AIM: The Future of Immunotolerance Treatment (FIT) group...

Descripción completa

Detalles Bibliográficos
Autores principales: Carcao, Manuel, Escuriola‐Ettingshausen, Carmen, Santagostino, Elena, Oldenburg, Johannes, Liesner, Ri, Nolan, Beatrice, Bátorová, Angelika, Haya, Saturnino, Young, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850066/
https://www.ncbi.nlm.nih.gov/pubmed/31033112
http://dx.doi.org/10.1111/hae.13762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850066/
https://www.ncbi.nlm.nih.gov/pubmed/31033112
http://dx.doi.org/10.1111/hae.13762

Ejemplares similares